Wall Street analysts expect that Trevena, Inc. (NASDAQ:TRVN) will report earnings per share of ($0.36) for the current quarter, Zacks reports. Zero analysts have provided estimates for Trevena’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.33). Trevena posted earnings of ($0.37) per share in the same quarter last year, which indicates a positive year over year growth rate of 2.7%. The business is expected to issue its next earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that Trevena will report full year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.14). For the next year, analysts forecast that the business will report earnings of ($0.94) per share, with EPS estimates ranging from ($1.17) to ($0.77). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Trevena.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.19.

Several equities analysts recently issued reports on the stock. ValuEngine cut shares of Trevena from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Needham & Company LLC boosted their price target on shares of Trevena from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, May 15th. HC Wainwright reiterated a “buy” rating on shares of Trevena in a research report on Monday, May 8th. Roth Capital set a $9.00 price target on shares of Trevena and gave the company a “buy” rating in a research report on Saturday, May 6th. Finally, Oppenheimer Holdings, Inc. set a $10.00 price target on shares of Trevena and gave the company a “buy” rating in a research report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company’s stock. Trevena currently has an average rating of “Buy” and an average target price of $11.73.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/20/trevena-inc-trvn-expected-to-post-earnings-of-0-36-per-share.html.

A number of large investors have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Trevena by 4.5% in the first quarter. FMR LLC now owns 7,037,804 shares of the biopharmaceutical company’s stock worth $25,828,000 after buying an additional 304,256 shares during the period. Citizens & Northern Corp boosted its stake in shares of Trevena by 87.2% in the first quarter. Citizens & Northern Corp now owns 54,300 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 25,300 shares during the period. Piermont Capital Management Inc. boosted its stake in shares of Trevena by 18.8% in the first quarter. Piermont Capital Management Inc. now owns 91,290 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 14,420 shares during the period. Sphera Funds Management LTD. acquired a new stake in shares of Trevena during the first quarter worth $429,000. Finally, American International Group Inc. boosted its stake in shares of Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,816 shares during the period. Institutional investors and hedge funds own 64.45% of the company’s stock.

Shares of Trevena (TRVN) traded down 0.34% during mid-day trading on Thursday, hitting $2.97. The stock had a trading volume of 547,147 shares. Trevena has a 1-year low of $2.15 and a 1-year high of $8.00. The firm’s market capitalization is $173.15 million. The stock’s 50-day moving average is $2.50 and its 200 day moving average is $4.04.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.